NCT02827071

Terminated

Ocular Imaging Study Using Advanced OCT

University of California, Los Angeles Source

Compare

Other study identifiers

Sponsor study identifier

JSEI Nidek Advanced OCT

Study Type

observational

Actual enrollment (reported)

150

Locations

1 country

Sites

1

Timeline

Study Start

July 2016

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 9, 2021

Actual (reported)

Study Completion

December 9, 2021

Actual (reported)

Brief Summary

The purpose of this study is to evaluate this AngioScan angiography software on patients with various retinal vascular disorders. The advanced OCT instrument is an FDA approved clinically used camera, but the AngioScan angiography software is not FDA approved. Investigators would like to know if this imaging device and software can improve the quality of images and visualization of imaged tissues and whether they are useful in the diagnosis and treatment of eye diseases. Images collected in this study may be compared to other images collected as part of standard of care on the same patient (OCT, FA, AF, Fundus).

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: terminated
Actual enrollment (reported): 150 participants
Study completion date: December 9, 2021
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
July 2016
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
July 6, 2016
Actual (reported)
First Posted
July 11, 2016
Actual (reported)
Primary Completion
December 9, 2021
Actual (reported)
Study Completion
December 9, 2021
Actual (reported)

Last Updated: April 20, 2026
Status Verified: July 2016
Last Update Submitted: April 16, 2026

Conditions

Macular Degeneration Retinal Vascular Disorder

Outcome Measures

Primary Outcomes (1)

Retinal vascular abnormalities imaged by OCT Angiography and en face analysis of macular disorders
2 years

Study Arms (1)

Retina abnormalities

Subjects with various retina vascular disorders

Eligibility Criteria

Age18 Years - 115 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Subjects with retinal vascular abnormalities

You may qualify if:

Any patient with abnormal retinal findings as determined by investigators.

You may not qualify if:

Sponsors & Collaborators

University of California, Los Angeles
Otherlead

Study Sites (1)

Stein Eye Institute/Geffen School of Medicine

Los Angeles, California, 90095, United States

MeSH Terms

Conditions

Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Enrollment

150 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 6, 2016

First Posted

July 11, 2016

Study Start

July 2016

Date type not reported

This date has not been verified as actual or estimated.

NCT00996684

Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration

Phase 2Unknown

NCT02555995

Assessment of Scan Quality of Sparse OCT Retina Scanner (MimoStudy01)

Not ApplicableCompleted

NCT00926913

Investigating Optical and Neural Causes of Vision Loss

Withdrawn

NCT04741763

"Night Vision and Carotenoids"

Not ApplicableCompleted

NCT03539549

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

Phase 2Completed

NCT02181517

A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Phase 2Completed

Those suffering from head, neck or other injury which makes them unable to position themselves in head restraint for imaging.
Participants who are unable to maintain retinal fixation on a specified target.
Participants unable to achieve sufficient pupil dilation and alignment stability for imaging to take place.
Patients with media opacity which preclude high quality imaging.

Contact the study team to confirm eligibility.

Primary Completion

December 9, 2021

Actual (reported)

Study Completion

December 9, 2021

Actual (reported)

Last Updated

April 20, 2026

Record last verified: 2016-07

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02827071
Data provider: ClinicalTrials.gov
Source updated: 2026-04-20
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:30:31 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Retina abnormalities

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations